Seattle Genetics traded at $175.13 this Wednesday July 6th, decreasing $1.64 or 0.93 percent since the previous trading session. Looking back, over the last four weeks, Seattle Genetics lost 21.31 percent. Over the last 12 months, its price rose by 16.96 percent. Looking ahead, we forecast Seattle Genetics to be priced at 175.23 by the end of this quarter and at 161.37 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,932.00 70.00 1.81% 7.73%
Astellas Pharma 2,144.00 17.50 0.82% 14.93%
Eisai 6,153.00 -14.00 -0.23% -41.29%
Daiichi Sankyo 3,521.00 46.00 1.32% 55.04%
AbbVie 152.27 -0.26 -0.17% 30.42%
Acadia Pharmaceuticals 15.12 -0.15 -0.98% -36.92%
Agios Pharmaceuticals 25.35 -0.10 -0.39% -55.38%
Amgen 244.76 -0.49 -0.20% 0.20%
Bayer 56.76 0.57 1.01% 12.17%
Biogen 217.04 1.06 0.49% -41.19%
Bluebird Bio 4.82 -0.23 -4.55% -84.51%
BioMarin Pharmaceutical 86.41 0.05 0.06% 4.06%
Bristol-Myers Squibb 75.80 -0.42 -0.55% 13.66%
Celldex Therapeutics 23.99 -0.76 -3.07% -17.13%
Clovis Oncology 2.18 -0.23 -9.54% -59.55%
Esperion Therapeutics 6.69 -0.30 -4.29% -65.25%
Exelixis 21.53 -0.74 -3.32% 19.81%
Genmab 2,432.00 17.00 0.70% -8.54%
Gilead Sciences 62.41 -0.32 -0.51% -8.70%
GlaxoSmithKline 1,804.80 14.60 0.82% 26.56%
Glaxosmithkline 43.11 -0.19 -0.44% 7.13%
Immunogen 5.15 0.25 5.10% -16.94%
Incyte Corp 79.75 0.03 0.04% -2.90%
Insmed 22.06 0.78 3.67% -20.82%
Karyopharm Therapeutics 5.22 -0.09 -1.69% -48.16%
Eli Lilly 328.29 -1.86 -0.56% 38.45%
MacroGenics 3.42 0.11 3.32% -87.76%
Merck & Co 93.00 -0.13 -0.14% 19.05%
Moderna Inc 164.08 4.52 2.83% -29.52%
Mirati Therapeutics 69.83 -2.13 -2.96% -56.07%
Nektar Therapeutics 3.90 -0.03 -0.76% -76.53%
Novartis 82.31 1.09 1.34% -2.14%
Puma Biotechnology 2.78 0.12 4.51% -66.34%
Pfizer 53.10 0.35 0.66% 35.29%
Regeneron Pharmaceuticals 591.82 -3.08 -0.52% 2.94%
Sanofi 98.66 0.76 0.78% 15.02%
Seattle Genetics 175.13 -1.64 -0.93% 16.96%
Spectrum Pharmaceuticals 0.81 0.01 1.24% -76.45%
Sarepta Therapeutics 75.97 0.23 0.30% 5.53%
Teva Pharmaceutical Industries Ltd 2,656.00 0 0% -14.29%
Vertex Pharmaceuticals 288.54 -2.62 -0.90% 45.92%
Xencor 32.44 1.99 6.54% -4.14%

Indexes Price Day Year
USND 11362 39.61 0.35% -22.52%

Seattle Genetics
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.